How to appeal an Independence Blue Cross prostate cancer denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Independence Blue Cross-specific note: BCBS licensee covering 5-county SE Pennsylvania (Philadelphia, Bucks, Chester, Delaware, Montgomery). Parent of AmeriHealth (NJ/DE). FutureScripts is the in-house PBM. PA Insurance Department oversees fully-insured complaints.

What Independence Blue Cross's policy requires for prostate cancer

Cited policy: BCBS Lynparza (Olaparib) for HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Adult mCRPC with deleterious or suspected-deleterious germline OR somatic HRR mutation (FDA-approved test). HRR panel per PROfound: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L. Prior progression on enzalutamide OR abiraterone (monotherapy indication). For PROpel combo (olaparib+abiraterone+prednisone): BRCA-mutated 1L mCRPC. Castrate testosterone <50 ng/dL. Olaparib 300 mg PO BID.

How Independence Blue Cross denies prostate cancer — and how to counter it

Where Independence Blue Cross pushes back: 1) Only BRCA1/2 covered; 2) HRR result must be germline only; 3) Insufficient ARSI failure for monotherapy.

Counter-arguments that hold up: PROfound NEJM 2020 Hussain — olaparib HRR-mutated mCRPC post-ARSI rPFS HR 0.34 (Cohort A BRCA/ATM) + 0.49 (overall HRR). FDA May 19, 2020 monotherapy label covers 14-gene HRR panel, NOT BRCA-only. Both germline AND somatic HRR mutations qualify per FDA label and NCCN v1.2025. PROpel NEJM Evid 2022 + Lancet 2023 — olaparib+abiraterone 1L mCRPC rPFS benefit (FDA narrowed combo label May 2023 to BRCA-mutated). NCCN v1.2025 Category 1 for HRR-mutated mCRPC post-ARSI.

What Independence Blue Cross typically denies for prostate cancer

Across Independence Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• Out-of-network for SE Pennsylvania providers
• AmeriHealth-administered plan denials
• Specialty drug PA via FutureScripts (PBM)
• Behavioral health network adequacy

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to Independence Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Independence Blue Cross cited in the denial.
3. File the appeal through Independence Blue Cross's portal (members: https://www.ibx.com ; providers: https://www.ibxpress.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Independence Blue Cross's prior-authorization criteria by drug: Independence Blue Cross PA criteria on ApprovalHelp.